Biologics Market (By Source: Microbial, Mammalian, Others; By Product: MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others; By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others; By Manufacturing: Outsourced, In-house; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biologics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biologics Market, by Source, 2023-2032
8.1.1. Microbial
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Mammalian
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2020-2032)
9.1. Biologics Market, by Product, 2023-2032
9.1.1. Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Vaccines
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. RecombinantProteins
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Antisense, RNAi & molecular therapy
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Cell Based Therapies
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
10.1. Biologics Market, by Indication, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Immunological Disorders
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cardiovascular Disorders
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Hematological Disorders
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
11.1. Biologics Market, by Manufacturing, 2023-2032
11.1.1. Outsourced
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. In-house
11.1.2.1. Market Revenue and Forecast (2020-2032)
12.1. Biologics Market, by Distribution Channel, 2023-2032
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Forecast (2020-2032)
13.1. North America
13.1.1. Market Revenue and Forecast, by Source (2020-2032)
13.1.2. Market Revenue and Forecast, by Product (2020-2032)
13.1.3. Market Revenue and Forecast, by Indication (2020-2032)
13.1.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Source (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Indication (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Source (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Indication (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Source (2020-2032)
13.2.2. Market Revenue and Forecast, by Product (2020-2032)
13.2.3. Market Revenue and Forecast, by Indication (2020-2032)
13.2.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Source (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Indication (2020-2032)
13.2.7. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Source (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Indication (2020-2032)
13.2.10. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Source (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Indication (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Source (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Indication (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Source (2020-2032)
13.3.2. Market Revenue and Forecast, by Product (2020-2032)
13.3.3. Market Revenue and Forecast, by Indication (2020-2032)
13.3.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Source (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Indication (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Source (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Indication (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Source (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Indication (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Source (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Indication (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Source (2020-2032)
13.4.2. Market Revenue and Forecast, by Product (2020-2032)
13.4.3. Market Revenue and Forecast, by Indication (2020-2032)
13.4.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Source (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Indication (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Source (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Indication (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Source (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Indication (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Source (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Indication (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Source (2020-2032)
13.5.2. Market Revenue and Forecast, by Product (2020-2032)
13.5.3. Market Revenue and Forecast, by Indication (2020-2032)
13.5.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Source (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Indication (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Source (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Indication (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1. Eli Lilly & Company
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Samsung Biologics
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. F Hoffman La Roche
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Celltrion Addgene
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Amgen
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbvie Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sanofi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Merck & Co. Inc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Novo Nordisk A/S
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client